Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) are frequently found in brain tumors, and the resulting onco–metabolite, 2–hydroxyglutarate (2HG), has been suggested to be a potential diagnostic and prognostic biomarker of the diseases. Indeed, recent studies have demonstrated the feasibility of non–invasively detecting 2HG by using proton magnetic resonance spectroscopy (1H–MRS). Due to severe spectral overlaps of 2HG with its background metabolites and spectral baselines, however, the majority of those previous studies employed spectral editing methods with long echo times (TEs) instead of the most commonly used short TE approach with spectral fitting. Consequently, the results obtained with spectral editing methods may potentially be prone to errors resulting from substantial signal loss due to relaxation. Given that the spectral region where the main signal of 2HG resides is particularly sensitive to spectral baseline in metabolite quantification, we have investigated the impact of incorporating voxel–specifically measured baselines into the spectral basis set on the performance of the conventional short TE approach in 2HG detection in rodent models (Fisher 344 rats; n = 19) of IDH1/2 mutant–overexpressing F98 glioma at 9.4T. Metabolite spectra were acquired (SPECIAL sequence) for a tumor region and the contralateral normal region of the brain for each animal. For the estimation of spectral baselines metabolite–nulled spectra were obtained (double–inversion–recovery SPECIAL sequence) for each individual voxels. Data were post–processed with and without the measured baselines using MRUI and LCModel—the two most widely used data post–processing packages. Our results demonstrate that in–vivo detection of 2HG using the conventional short TE approach is challenging even at 9.4T. However, incorporation of voxel–specifically measured spectral baselines may potentially improve its performance. Upon more thorough validation in a larger number of animals and more importantly in human patients, the potential utility of the proposed short TE acquisition with voxel–specific baseline measurement approach in 2HG detection may need to be considered in the study design.
Citation: Heo H, Kim S, Lee HH, Cho HR, Xu WJ, Lee S-H, et al. (2016) On the Utility of Short Echo Time (TE) Single Voxel 1H–MRS in Non–Invasive Detection of 2–Hydroxyglutarate (2HG); Challenges and Potential Improvement Illustrated with Animal Models Using MRUI and LCModel. PLoS ONE 11(1): e0147794. doi:10.1371/journal.pone.0147794
Editor: Petras Dzeja, Mayo Clinic, UNITED STATES
Received: July 22, 2015; Accepted: January 9, 2016; Published: January 28, 2016
Copyright: © 2016 Heo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: This study was supported by a grant from the Ministry for Health, Welfare & Family Affairs (HI13C0015) in Korea.
Competing interests: The authors have declared that no competing interests exist.
Glioblastomas and malignant gliomas are the common phenotypes of brain tumors. They are the most aggressive diffuse gliomas of astrocytic lineage [1, 2] with poor prognosis and lower survival. According to the World Health Organization (WHO) Classification of Tumors of the Central Nervous System, mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) are found in grade II and III astrocytomas and oligodendrogliomas, and in grade IV glioblastomas [3, 4]. IDH is a nicotinamide adenine dinucleotide phosphate (NADP+)–dependent enzyme, which normally catalyzes the oxidative decarboxylation of isocitrate to α–ketoglutarate (α–KG). Most of IDH1 mutations occur at a single amino acid residues, R132 (predominantly R132H), in the active site of the enzyme [4, 5]. For IDH2 mutations, the disease–associated single residual mutations are highly present at the R172 residue (predominantly R172K) [4, 6]. These IDH1/2 mutants acquire a new enzymatic ability to catalyze the NADPH–dependent reduction of α–KG to 2–hydroxyglutarate (2HG) . Because it is an error product of abnormal metabolism in brain tumors with IDH mutation, 2HG is considered an onco–metabolite . Together with the implication of the IDH mutational status with patient survival duration , therefore, developing a noninvasive means of detecting 2HG would have a great diagnostic and prognostic value [9–11].
Proton magnetic resonance spectroscopy (1H–MRS) has been extensively used for quantification of metabolites in vivo. Typically in these days, 1H–MRS spectra are acquired at the shortest echo time (TE) attainable in order to minimize signal loss resulting from relaxation and, for coupled spins, J–evolution. Then, spectral fitting is performed for quantification of individual metabolites. Indeed, recent 1H–MRS studies have clearly demonstrated its potential ability to non–invasively detect the presence of 2HG in glioma patients with IDH mutations [9, 10, 12]. However, due to the severe spectral overlaps of 2HG signal with its background metabolite signals (e.g., gamma–aminobutylic acid (GABA), glutamate (Glu), glutamine (Gln), and N–acetylaspartylglutamate (NAAG)) [9, 10], the majority of those previous studies [9, 10] had to employ spectral editing methods  with a long TE indispensably where those background metabolite signals are either effectively suppressed by taking advantage of different J–evolution of different coupled spin systems  or avoided by J–difference editing [9, 10]. Thus, the resulting 2HG concentrations are prone to quantitative errors due to substantial signal loss over such a long TE as previously discussed [10, 14]. The quantification of metabolites other than 2HG can also be challenging in the edited spectra due to the same signal loss mechanisms, which may also be important for better understanding of the pathogenesis and progression of brain tumors with gene mutations [15–17]. Thus, the conventional short TE approach is still desired despite its reported limitation in the detection of 2HG [9, 12, 14].
Previous studies have demonstrated the strong dependence of the accuracy of metabolite quantification on the characteristics of spectral baseline [18–20] that is mainly contributed by macromolecules (MMs) at short TE . In particular, quantification of Glu and Gln is known to be most influenced by baseline [18, 19] and the difficulty of separating Glu and Gln had been attributed more to baseline than to their spectral overlaps . Therefore, given that the main signal of 2HG directly overlaps with both Glu and Gln [9, 10], and that measured baselines provide more information than those modelled , potential impact of incorporating measured baselines into the spectral basis set on the detection of 2HG at short TE should be an important issue, which has not been addressed in the previous 1H–MRS 2HG studies [9, 10, 12, 14]. It should also be noted that all those previous studies used LCModel  for metabolite quantification. While LCModel is most commonly used for 1H–MRS data post–processing in frequency–domain, MRUI  is another frequently used software package  employing time–domain analysis. While the overall performance of such frequency– or time–domain spectral analyses were reported to be comparable on the one hand [25–27], they are also known to have their own characteristics  on the other hand.
To this end, we have assessed the performance of the conventional short TE 1H–MRS in the detection of 2HG in a rodent model of IDH1/2 mutant–overexpressing F98 glioma at 9.4T. Spectral baselines were obtained for each individual voxels, and data were post–processed by using both MRUI and LCModel with and without the incorporation of the measured baselines into the spectral basis set [18, 20]. Based on the results, technical challenges and potential strategies are discussed for the improvement of the efficacy of the short TE approach in the detection of 2HG in vivo.
Materials and Methods
The animal research protocol was approved by the Institutional Animal Care and Use Committee (IACUC) of Seoul National University Hospital. Prior to MR data acquisition, rats were anesthetized in a chamber with isoflurane (1.5% in oxygen). Rats were anesthetized with 20mg/kg of Zoletil® 100 (tiletamine–zolazepam, Virbac, Carros, France) for glioma implantation. Rats were euthanized by using CO2.
F98 glioma culture
Rat F98 glioma cells were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA) and were grown as previously described . Briefly, F98 cells were maintained in Dulbecco’s modified Eagle medium (DMEM) with 10% fetal bovine serum (FBS) at 37°C. To express IDH1 wild–type (IDH1–WT), IDH1–R132H, IDH2 wild–type (IDH2–WT), IDH2–R172K, and Mock transgenes, F98 cells were transfected with lentivirus for 24 h in the presence of 4–8 μg/mL polybrene. Transfected cells were passed for no more than 10 passages. These cells were maintained in DMEM including 10% FBS and penicillin (Hyclone, Logan, UT, USA). The cells were cultured at 37°C and 5% CO2 in a 90% humidified incubator.
Construction and preparation of lentiviral vectors
The IDH1/2 lentiviral vectors were prepared as previously described . Specifically, the genes for human IDH1 (GenBank accession number NM_005896) and IDH2 (GenBank accession number NM_002168) were obtained from Origene (Rockville, MD, USA), PCR amplified, and cloned into lentiviral vector CD526A–1 (System Biosciences, Mountain View, CA, USA). IDH1–R132H and IDH2–R172K were amplified with the above clones as templates using standard site directed mutagenesis. The cloned inserts were expressed under enhanced constitutive suCMV promoter. The sequences of the cloned genes were confirmed by ABI BigDye® Terminator Cycle Sequencing Kit (Foster city, CA, USA). The recombinant lentivirus was produced by SeouLin Bioscience Institute (Daejon, Korea). Expression of lentiviral particles was produced in HEK–293T cells cultured in DMEM including 10% FBS and collected after 48 h. Then, the virus was filtered through 0.45 μm membrane filter (Millipore, Billerica, MA, USA), and immediately stored at -70°C. Titer was determined by the TCID50 method and the concentrated titer was 2×107 IFU/mL.
The protein levels of F98 IDH1 –WT/–R132H, IDH2 –WT/–R172K, and Mock gliomas were evaluated by immunoblot analysis. Cells were lysed in ice–cold lysis buffer composed of 20 mM Tris–HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM β–glycerophosphate, 1 mM Na3VO4, 1 μg/mL leupeptin, and protease inhibitor cocktail (Sigma, MO, USA), and the concentration of lysate protein was evaluated with the bicinchoninic acid method (Pierce Biotechnology, Rockford, IL, USA). Approximately 50 μg of protein was loaded in each lane of a polyacrylamide denaturing gel for electrophoresis. After electrophoresis, the protein was transferred to nitrocellulose membranes for blotting. We used a rat monoclonal antibody to IDH1 (Dianova, Hamburg, Germany), a mouse monoclonal antibody to IDH1–R132H (Dianova), a rabbit polyclonal antibody to IDH2 (Proteintech, Chicago, IL, USA), a mouse monoclonal antibody to IDH2–R172K (NewEast Biosciences, King of Prussia, PA, USA), and a rabbit polyclonal antibody to β–actin (Abcam, Cambridge, UK). Primary antibodies were detected by horseradish peroxidase–conjugated antibodies (Santa Cruz Biotechnology, Paso Pobles, CA, USA).
F98 rat glioma implantation
The animal research protocol was approved by the Institutional Animal Care and Use Committee (IACUC). Six–week–old Fisher 344 female rats (F98 IDH1–WT, n = 3; F98 IDH1–R132H, n = 3; F98 IDH2–WT, n = 3; F98 IDH2–R172K, n = 10) with orthotopic brain tumors were used. Rats were anesthetized with 20mg/kg of Zoletil® 100 (tiletamine–zolazepam, Virbac, Carros, France). Rats were mounted on a stereotactic frame. A midline scalp incision was performed, followed by identification and exposure of the bregma. For induction of the brain tumors, stable gene transferred F98 cells were transplanted into the right striatum by using a 10 μL Hamilton syringe (AP, 1.0 mm; ML, 3.0 mm; DV, 5.5 mm). The needle was then slowly withdrawn. Rats were given a continuous one–layer suture, and post–care was performed in the cage.
MR data collection
In vivo 1H–MRS was performed at 2 weeks after the implantation of F98 glioma cells. Prior to data acquisition, rats were anesthetized in a chamber with isoflurane (1.5% in oxygen), and placed in the magnet in the prone position. During data acquisition anesthesia was maintained (1.0–1.5% isoflurane in oxygen) and the respiration and body temperature of the animals were monitored.
All MR data were collected on a 9.4T MR scanner (Agilent 9.4T/160AS; Agilent Technologies, Santa Clara, CA, USA) using a single channel surface coil (20 mm in diameter; Agilent Technologies) for both radio–frequency (RF) transmission and signal reception. Scout images were acquired by using a gradient echo sequence for all three orthogonal directions (repetition time (TR)/echo time (TE) = 55/2.75 ms, field–of–view (FOV) = 50×50 mm2, matrix size = 128×128, 10 slices for each direction (no gap), slice thickness (TH) = 1 mm, receiver bandwidth (BW) = 50 kHz, 1 signal average). Additional anatomical images were acquired in the axial direction using a T2–weighted fast spin echo sequence (TR/TE = 3000/30 ms, echo train length (ETL) = 4, FOV = 35×35 mm2, matrix size = 192×192, number of slices = 15 (no gap), TH = 1 mm, receiver BW = 100 kHz, 2 signal averages).
Based on the anatomical images, 1H–MRS voxels were defined in a tumor region (tumor VOI) and the contralateral normal region (CN VOI) of the brain for each animal. The voxel volumes were slightly adjusted depending on the tumor size, and the 1st–and 2nd–order shimming was performed over the voxels. 1H–MRS data were acquired with a SPECIAL sequence  (TR/TE = 4000/2.83 ms, spectral BW = 5 kHz, 2048 data points, 384 signal averages). A 0.6 ms (BW = 4.4 kHz) slice–selective Gaussian pulse was used for excitation. For inversion and refocusing a 3 ms (BW = 6.6 kHz) and a 1.3 ms (BW = 15.6 kHz) hyperbolic secant adiabatic full passage (AFP) pulses were used, respectively. To minimize voxel displacement , the carrier frequencies of the RF pulses of the SPECIAL sequence were adjusted by -2.3 ppm from the water resonance. A 32–step phase cycling was employed. Both a VAPOR water suppression  and an outer volume suppression (OVS) modules were also used .
For the estimation of spectral baselines, metabolite–nulled spectra  were also acquired for all voxels using a double inversion [23, 34, 35] SPECIAL sequence with nonselective hyperbolic secant pulses for inversion (duration = 3 ms and BW = 6.6 kHz). The first and the second inversion times (TI1 and TI2, respectively) were optimized according to the previous reports [23, 34, 35]. Briefly, a TI2 was determined first in consideration of the duration of the VAPOR and OVS modules. Then, using the T1’s of metabolites reported previously at 9.4T , a TI1 for metabolite nulling was obtained for each individual metabolites [34, 35], from which a compromised, optimal TI1 was determined . The sequence parameters for the optimized double inversion SPECIAL sequence were; TI1/TI2/TR = 2830/680/4650 ms, 320 signal averages. The rest of the sequence parameters were identical to those used for the metabolite quantification. Metabolite–nulled spectra at a long TE (TE = 30 ms, 160 signal averages) were also acquired to examine residual metabolite signals and validate optimal inversion parameters (data not shown).
Water–unsuppressed spectra were also collected from all voxels for the estimation of water content, and as a measure of SNR and linewidth of the spectra (32 signal averages).
Following the MRS scan, rats were sacrificed, and brain tissues were collected for each VOI, and frozen on dry ice. The tissues were then stored at -80°C.
Liquid chromatography–mass spectrometry (LC–MS)
The 2HG levels were measured using liquid chromatography–mass spectrometry (LC–MS). All tumor VOI samples (IDH1/2–WT, n = 6; IDH1/2–MT, n = 13) and six of the CN VOI samples were analyzed. Specifically, the frozen tissues were weighed, thawed at room temperature and homogenized with 300 μL mixture composed of methanol, acetonitrile, and distilled water (5:3:2). The samples were centrifuged at 28,000 g for 30 minutes, and the supernatants were used as the analytes. Quantitative analyses were performed by using an Agilent 1100 Series liquid chromatography system (Agilent, CO, USA). Sample separation was achieved by injecting 2 μL samples into a ZIC–pHILIC polymeric beads peek column (150×2.1 mm, 5 μm, Merck, Germany) at 35°C with a 0.15 mL/min flow rate. 10 mM ammonium carbonate (pH = 8.9) in distilled water was used as mobile phase A, and acetonitrile (ACN) as mobile phase B. The linear gradient was used as follows: 80% B at 0 minute, 35% B at 10 minutes, 5% B at 12 minutes, 5% B at 25 minutes, 80% B at 25.1 minutes, and 80% B at 35 minutes. Mass spectra were obtained in negative ion mode using an API 2000 Mass Spectrometer (AB/SCIEX, Framingham, MA, USA). The ESI source operation parameters were: -4.5 kV of ion spray and the heater (turbo) gas temperature at 350°C. Multiple reaction monitoring (MRM) was performed and controlled by Analyst 1.6 Software.
1H–MRS data analysis by MRUI and LCModel
Processing of metabolite–nulled spectra.
The metabolite–nulled spectra acquired for each individual voxels were analyzed by MRUI (v. 5.0). Given the low signal yield of spectral baseline in the metabolite–nulled spectra with respect to that in the metabolite spectra resulting from double inversion  as well as from the lower number of signal averages (320 vs. 384), the metabolite–nulled spectra were apodized  such that the SNR of the MM resonance at ~0.9 ppm therein was comparable to that in the metabolite spectra. Then, HLSVD filter  was applied to remove unwanted signal.
Metabolite quantification using MRUI after FID–truncation (FID–truncation+MRUI).
To investigate the impact of incorporating measured baseline into the spectral fitting on 2HG detection by using MRUI, first, initial data points of the free induction decays (FIDs) of the metabolite spectra were truncated for the removal of MM signal [23, 35, 39, 40]. The number of data points to be truncated was determined empirically [23, 35, 41]. That is, the SNR of the total creatine (tCr; ~3.0 ppm) and N–acetylaspartate (NAA; ~2.0 ppm) peaks and the reduction of MM signal were examined for all spectra by varying the number of truncated FID points from 1 to 30. Then, an optimal number of truncated FID points was determined to be 12.
The spectral bases for a total of 19 metabolites were created by using GAMMA  by referring to the previously reported chemical shifts and J–coupling constants of the metabolites [10, 43]. As a routine, data were zero–filled to 4096 points and, after Fourier transformation, line–broadened (~7 Hz) and phase–corrected. Residual water signal was removed by the HLSVD filter. Finally, individual metabolites were quantified by using QUEST .
Metabolite quantification using MRUI with measured baseline (voxel–specific baseline+MRUI).
The preprocessed metabolite–nulled spectra were included in the spectral basis set voxel–specifically, followed by the routine procedure for metabolite quantification.
Metabolite quantification using LCModel with simulated (built–in) baseline (simulated baseline+LCModel).
1H–MRS data were processed by using LCModel (v. 6.3–1J) with the same metabolite basis set that was used with MRUI. The built–in, vendor–provided, modeled MM and lipid components were included in the spectral fitting.
Metabolite quantification using LCModel with measured baseline (voxel–specific baseline+LCModel).
The preprocessed metabolite–nulled spectra were included in the spectral basis set voxel–specifically. The built–in, modelled MM and lipid components were excluded in the fitting process in order to minimize over–parameterization of the analysis , while retaining the spline function.
Processing of water–unsuppressed spectra.
The water–unsuppressed data were processed by using MRUI with the routine procedure. The SNR of water signal was estimated by dividing the peak amplitude by the standard deviation of noise measured in the 8–10 ppm range. The linewidth of water signal was estimated from the full–width–at–half–maximum.
The 2HG content estimated by 1H–MRS was normalized to that of water (to be denoted as 2HGMRS wherever in need of distinction from the 2HG content estimated by LC–MS (2HGLC–MS)).
Combined data analysis.
First, the voxels from F98 IDH1/2 WT/MT and CN VOI were stratified into Group A and Group B according to their 2HG content (relative intensity (RI)) measured by LC–MS (2HGLC–MS). The Group A and Group B were then considered as 2HG–absent and 2HG–present, respectively. Given the limited SNR and spectral dispersion of 1H–MRS spectra, those samples with intermediate 2HGLC–MS were excluded in the final data analysis. A Cramer–Rao lower bound (CRLB) of less than 20% [10, 14, 46] was considered as indicating successful spectral fitting. According to the 2HGMRS and associated CRLBs, the detection outcome with 1H–MRS was classified into true positive (Tp), false positive (Fp), true negative (Tn), false negative (Fn), and uncertain (U; CRLB>20%) cases.
To address those uncertain cases with CRLB>20%, as an illustration, the relationships between 2HGLC–MS and 2HGMRS were obtained by linear regression for each of the voxel–specific baseline+MRUI and the voxel–specific baseline+LCModel data including only those MRS data with correct detection. Using these relationships, the highest 2HGLC–MS in Group A (2HG–absent) was converted into 2HGMRS values, which were then defined as the cutoff 2HGMRS values for 2HG–absent voxels. That is, those voxels with CRLB>20% were considered either 2HG–absent or 2HG–present [12, 14] according to these cutoff 2HGMRS values in this study.
All results are expressed in mean±standard deviation (SD).
Establishment of F98 glioma cell lines for IDH –WT and –R132H/–R172K expression
After gene transfer into F98 glioma cell lines with lentiviral vectors containing IDH1/2–WT–GFP, IDH–R132H/–R172K–GFP, or empty–mock–GFP expression codons (Fig 1A), GFP–expressing F98 cells represented ~95.8–99.1% of the total population (Fig 1B). The fluorescent microscopic images (Fig 1C) and the immunoblot analysis (Fig 1D) further confirmed the well–established F98 glioma cell lines for the IDH1/2–WT and IDH–R132H/–R172K expressions.
(A) Construction map of IDH1/2–WT or –R132H/–R172K lentiviral vector. (B) GFP expressions in Mock, IDH1/2–WT or –R132H/–R172K vector transduced F98 cells by using Fluorescence–activated cell sorting (FACS). (C) GFP–tagged gene expressions of the F98 cells confirmed by fluorescent microscopic images. (D) Immunoblot analysis where IDH1–R132H or IDH2–R172K specific antibodies were detected only in the mutated epitopes of F98 IDH1–R132H or IDH2–R172K, respectively.
2HG levels in the samples as measured by LC–MS (2HGLC–MS)
The 2HGLC–MS values in the brain samples are shown in Fig 2. Based on these 2HGLC–MS values, samples were classified into Group A (n = 12; 2HG–absent) and Group B (n = 7; 2HG–present). Given the limited SNR and spectral dispersion of 1H–MRS, those 6 samples with intermediate 2HGLC–MS were excluded from the further analysis. The lowest 2HGLC–MS in Group B was more than 20 times higher than the highest 2HGLC–MS in Group A.
The brain samples were collected from the tumor regions (F98 IDH1/2–WT, IDH1–R132H, and IDH2–R172K) and the contralateral, normal regions (CN VOI). The relative intensity of 2HG in Group A (n = 12) and Group B (n = 7) ranged 0.06x105~0.15x105 and 3.14x105~5.47x105, respectively. Those 6 samples with intermediate 2HG levels (3 from IDH1–R132H and 3 from IDH2–R172K) were excluded in the final data analysis, and then the Group A and Group B were treated as 2HG–absent and 2HG–present, respectively.
Representative 1H–MRS spectra are shown in Fig 3 for a CN VOI (Fig 3A and 3C) and a tumor VOI (Fig 3B and 3D), which were post–processed by either MRUI (Fig 3A and 3B) or LCModel (Fig 3C and 3D) with the voxel–specifically measured spectral baselines. The baselines for CN VOI are in good agreement with those previously reported at the same field strength .
(A and C) A contralateral normal brain region (CN VOI). (B and D) A brain tumor region (tumor VOI) with F98 IDH2–R172K glioma. All spectra were post–processed with voxel–specifically obtained spectral baselines by using either MRUI (A and B) or LCModel (C and D). The resulting residual of fit and the 2HG spectral components are also shown, which were denoted by dashed lines in ~1.8–2.3 ppm. (2HG: 2–hydroxyglutarate, GABA: gamma–aminobutylic acid, Gln: glutamine, Glu: glutamate, Lac: lactate, mI: myo–inositol, NAA: N–acetylaspartate, NAAG: N–acetylaspartylglutamate, Tau: taurine, tCho: total choline, tCr: total creatine, tNAA: total N–acetylaspartate).
The mean linewidth and SNR of water peaks in the water–unsuppressed spectra were 15.05±3.31 Hz and 1.72×103±4.06×102, respectively, for the mean voxel volume of 9.58±1.73 mm3.
Impact of voxel–specific baseline on 2HG detection by 1H–MRS
The results of 2HG detection by 1H–MRS are summarized in Table 1.
Tn, true-negative; Tp, true-positive; Fn, false-negative; Fp, false-positive; U, uncertain case (CRLB >20%); n/a, not available;
For the FID–truncation+MRUI, there were 10 correctly detected (true negative) and 2 uncertain cases out of 12 in Group A. There were 3 correctly detected (true positive), 2 incorrect (false negative), and 2 uncertain cases out of 7 in Group B. The overall percentage of correct detection (either true positive or true negative) of 2HG with this method was ~68% (13/19). For the voxel–specific baseline+MRUI, there were 9 correctly detected and 3 uncertain cases in Group A. There were 6 correctly detected and 1 uncertain cases in Group B. Thus, by incorporating the voxel–specifically measured baselines into the quantitative analysis, the overall percentage of correct detection of 2HG was improved to ~79% (15/19). In particular, the sensitivity (correct detection for 2HG–present voxels) was greatly improved from ~43% (3/7) to ~86% (6/7), and the total number of incorrect detection was reduced from 2 to none.
For the simulated baseline+LCModel, there was no correctly detected case with 8 incorrect (false positive) and 4 uncertain cases out of 12 in Group A. On the other hand, 2HG was correctly detected for all 7 voxels in Group B. The overall percentage of correct detection of 2HG with this method was ~37% (7/19). For the voxel–specific baseline+LCModel, there were 4 correctly detected and 8 uncertain cases in Group A. There were 5 correctly detected cases with 1 incorrect and 1 uncertain cases in Group B. The overall percentage of correct detection of 2HG was improved to ~47% (9/19). Importantly, the total number of incorrect detection was drastically reduced from 8 to 1 by incorporating the measured baselines.
Addressing uncertain cases with CRLB > 20% by defining cutoff 2HGMRS
In order to deal with those uncertain cases with CRLB>20% in the results obtained with measured baselines, which took considerable portions (4/19 for MRUI and 9/19 for LCModel), particularly for Group A, cutoff 2HGMRS values for each of the MRUI and the LCModel data were defined based on the relationships between 2HGLC–MS and 2HGMRS. The linear regression resulted in 2HGMRS = (0.96 × 2HGLC–MS (×10−5)) + 0.06 for MRUI (r = 0.79, p<0.001) and 2HGMRS = (1.06 × 2HGLC–MS (×10−5)) + 0.36 for LCModel (r = 0.81, p = 0.008).
By converting the highest 2HGLC–MS in Group A into 2HGMRS, the resulting cutoff 2HGMRS for 2HG–absent voxels were 0.20 and 0.52 for MRUI and LCModel, respectively. Using these cutoff values, for the voxel–specific baseline+MRUI, there were 10 correctly detected cases out of 12 in Group A. All 7 cases were correctly detected in Group B. The overall percentage of correct detection of 2HG was further improved to ~89% (17/19). For the voxel–specific baseline+LCModel, there were 6 correctly detected cases out of 12 in Group A. Six out of 7 cases were correctly detected in Group B. The overall percentage of correct detection of 2HG was improved to ~63% (12/19). Thus, compared to those results without measured baselines, the overall percentages of correct detection were improved from ~68% to ~89% for MRUI, and from ~37% to ~63% for LCModel. In particular, the sensitivity of MRUI was improved from ~43% to 100%, and the specificity of LCModel was improved from 0% to 50%. The resulting mean 2HGMRS for the correctly detected cases in Group B were 3.97±2.56 for MRUI and 4.80±1.15 for LCModel.
In this report we have investigated in animal models of brain tumors at 9.4T the potential impact of incorporating voxel–specifically measured baselines into the basis set on the noninvasive detection of 2HG by using short TE 1H–MRS in combination with MRUI and LCModel. To address 2HGMRS with CRLB>20%, as an illustration, we have defined cutoff 2HGMRS values for 2HG–absent voxels.
We used F98 glioma cells transfected with human IDH1/2 gene–cloned lentiviral vectors and implanted in rat brain. F98 anaplastic glioma clone is classified as a malignant brain tumor, and known to show an infiltrative growth pattern analogous to that of human GBM . The overexpression of IDH1/2 mutations and overproduction of 2HG in our animal models were clearly shown.
The main resonance of 2HG signal resides in ~2.0–2.5 ppm where signals from at least 4 other metabolites (GABA, Glu, Gln, and NAAG) [9, 10] also contribute. The severe spectral overlap is exacerbated by the presence of MMs—the primary component of spectral baseline, and lipid in the case of fat infiltration that is often accompanied in patients with brain tumors [47, 48]. For this reason, the majority of those previous studies have employed spectral editing methods for the detection of 2HG with relatively long TEs [9, 10] either for effective suppression of background metabolite signal  by taking advantage of different J–evolution of different coupled spin systems  or as a consequence of using a pair of spectral editing pulses with a relatively long pulse duration in order to achieve high spectral selectivity [9, 10]. Given the strong dependence of the accuracy of metabolite quantification on spectral baseline [18–20] and its relatively short T2 , such long TEs employed in spectral editing methods are clearly beneficial on the one hand [10, 49, 50]. On the other hand, as discussed by the authors [10, 14], the resulting 2HG content may be prone to quantitative errors resulting from substantial signal loss due to relaxation. In addition, the signal loss arising from both relaxation and, for coupled spins, J–evolution of spins can also render precise quantification of metabolites other than 2HG challenging in the edited spectra, which may also be important for better understanding of the pathogenesis and progression of brain tumors with gene mutations and for the development of novel therapeutic strategies [15–17]. For instance, the reduction of Glu levels resulting from the decreased activity of the branched–chain amino acid transaminase 1 (BCAT1) enzyme has been suggested to be strongly associated with the pathogenesis of the IDH1 mutated gliomas [15, 51]. As well, the down–regulation of glutathione (GSH) in IDH1 mutated gliomas was suggested as a potential therapeutic target . Therefore, together with the fact that short TE 1H–MRS is most commonly used in metabolite quantification without the need of pulse sequence programming and sequence optimization procedure, improvement of the performance of such a conventional short TE approach is important. To this end, the previous reports that among MR–visible metabolites Glu and Gln are most influenced by baseline [18, 19, 22], and the fact that the 2HG signal directly overlaps with Glu and Gln, both dictate the investigation of the potential impact of voxel–specifically measured baselines on the 2HG detection.
To address this issue, first, for the comparison purpose, 2HG was quantified without measured baselines by using FID–truncation in combination with MRUI (FID–truncation+MRUI) and by using the current version of LCModel with built–in MM and lipid modelling (simulated baseline+LCModel). Using these methods, our results corroborate even at 9.4T those previously reported technical challenges in the detection of 2HG at short TE [9, 12, 14]. In our study, excellent specificity but with relatively low sensitivity was obtained for the FID–truncation+MRUI. For the simulated baseline+LCModel, excellent sensitivity was obtained but with no true negative case. Such relatively low specificity and high sensitivity with LCModel in the detection of 2HG has also been reported in a recent human study . The FID–truncation employed in our study is simple to perform and frequently used for the removal of MM signal when measured baselines are not available, and its performance has been reported previously [23, 35, 39, 40]. Therefore, while it results in SNR reduction in the spectra to a certain extent particularly for those metabolites with relatively short T2, the FID–truncation method in combination with MRUI is a reasonable approach for the investigation of the impact of measured baselines on 2HG detection. For LCModel, such FID–truncation can also be performed. However, the current version of LCModel used in our study already employs an extended basis set including modeled MMs and lipids [45, 47, 48, 52], and therefore does not require a prior knowledge about baselines.
By incorporating voxel–specifically measured baselines, the overall performance of both MRUI and LCModel were improved. In particular, the total numbers of incorrect detection were substantially reduced for both MRUI (from 2 to none) and LCModel (from 8 to 1) prior to addressing those uncertain cases with CRLB>20%. In clinical practice, uncertain or indeterminate diagnostic cases can occur, for which a follow–up examination is usually performed. Thus, false diagnosis is far more problematic than uncertain cases. In this regard, the drastic reduction of incorrect detection of 2HG by incorporating measured baselines in our study clearly demonstrates the advantage of this approach. While the retrieved SNR of the spectra with respect to that with FID–truncation in the case of MRUI needs to be accounted for to a certain extent, the improved 2HG detection by using measured baselines reconfirms the strong dependence of quantitative outcome on the baseline as previously reported [18–20]. The improved performance, in turn, also indicates the difficulty of modeling MMs and lipids due to their variability in vivo. The current version of LCModel has model spectra for MMs and lipids, and to avoid over–parameterization of the analysis several spectral components were combined into a single component (e.g., MM resonances at 1.95, 2.08 and 2.25 ppm combined into a single component (i.e., ‘MM20’), and lipid resonances at 2.04, 2.25 and 2.8 ppm combined into ‘Lip20’) followed by a soft constraint imposed on the ratios between lipid components and between MM components (i.e., ‘Concentration Ratio Priors’) [45, 47]. By this sophisticated modeling, LCModel is known to better separate between MMs and lipids . However, for instance, the proportion or relative intensity of the lipid resonances can differ for different lipid composition [47, 53]. As well, while in LCModel the residual of fit even after using the currently implemented modeled MM and lipid baselines is supposed to be accounted for by the calculated spline function, these combined strategies may not be as good in performance as voxel–specifically measured baselines, particularly at high field [20, 23].
Even with the measured baselines, the performance, esp., the specificity, with both MRUI and LCModel requires further improvement, which again demonstrates the challenges of 2HG detection at short TE even at 9.4T. This was mainly due to the presence of those uncertain cases (CRLB>20%). Such uncertain cases are frequently encountered [9, 10, 12, 14], which most likely result from the limited SNR and spectral dispersion of 1H–MRS spectra. In the cases with CRLB>20%, previous studies implicitly regarded those relatively low 2HG concentrations as 2HG–absent , and those relatively high 2HG concentrations as 2HG–present  with no defined cutoff value. For an effectively isolated 2HG peak from both background metabolites and spectral baselines as in the cases with spectral editing methods [9, 10], at least a threshold concentration of 2HG for reliable detection can be determined by using simulation or in phantom for a given SNR of spectra . However, at short TE, such preliminary analysis is difficult due to the severe spectral overlaps of 2HG with background metabolites and spectral baselines, the concentrations of both of which can vary in vivo. For this reason, we have resorted, as an illustration, to the relationships between the 2HGLC–MS and the correctly detected 2HGMRS, given that the Group A and Group B were stratified based on the 2HGLC–MS values. Using this approach, the overall percentages of correct detection of 2HG were further improved. In particular, the sensitivity of MRUI was improved from ~43% to 100%, and the specificity of LCModel was improved from 0% to 50%. Such a cutoff 2HGMRS for 2HG–absent voxels may also be defined, for instance, from the mean 2HGLC–MS between the highest 2HGLC–MS in Group A and the lowest 2HGLC–MS in Group B, instead of from the highest 2HGLC–MS in Group A alone. However, in our study, those uncertain cases occurred far more often in Group A, for which 2HGMRS values should tend to be small. Therefore, the cutoff 2HGMRS converted from the highest 2HGLC–MS in Group A should be more reasonable. Although not attempted in our study due to the small number of samples, such a cutoff 2HGMRS may be better defined, for instance, empirically from a preliminary study, in which case cutoff 2HGMRS values should be determined in conjunction with both SNR and linewidth of spectra that are known to simultaneously influence fitting precision . This means that such a cutoff value needs to be determined specific to a given experimental setting including imaging parameters and the choice of a data post–processing software. Once a cutoff 2HGMRS is defined retrospectively from a preliminary study, uncertain cases may then be prospectively addressed in the following studies.
Previous studies reported comparable performance of time–domain and frequency–domain analyses in metabolite quantification [25–27]. Although in our study such a direct comparison between the two approaches is difficult due to the small sample size, substantial improvement in the detection of 2HG by employing voxel–specifically measured baselines was seen for both. The resulting 2HGMRS values from LCModel tend to be higher than those from MRUI. Such an overestimation of frequency–domain quantification relative to time–domain approach has also been reported previously .
Our study has limitations. Overall, the improved performance of the short TE MRS approach with the proposed method has been demonstrated. However, the current results presented in our study does not strongly support its applications directly to the diagnosis of each individual patients. Prior to clinical applications, the proposed method should be validated in a larger number of animals and animal groups with different 2HG content, and more importantly in human patients with resulting sensitivity and specificity acceptable to radiologists and neurosurgeons. Although there were strong correlations between 2HGLC–MS and 2HGMRS in our study, the measurement errors can also result from biological variability. For this reason, we have excluded in the final data analysis those samples with intermediate 2HGLC–MS, and focused our analysis on the detection rather than quantification of the onco–metabolite with only two animal groups of 2HG–absent and 2HG–present. The highest 2HGLC–MS in the former was more than 20 times lower than the lowest 2HGLC–MS in the latter. Metabolite–nulled spectra estimated by using an inversion recovery technique are prone to residual metabolite signal [20, 23]. To minimize such contamination of baseline spectra, however, we have employed a double inversion technique [23, 34, 35]. The baseline spectra resulting from double inversion are known to be subject to T1–weighting and low signal yield . Increasing the number of signal averages to retrieve the signal would require a prohibitively long scan time. For this reason, the metabolite–nulled spectra were apodized in our study as previously reported , which also facilitates the smoothness of baseline that is commonly assumed in the baseline modeling . Our metabolite–nulled spectra for CN VOIs are in close agreement with those previously reported using rat brain at the same field strength . In our study, a calculated metabolite basis set was used instead of those measured in phantom. However, the performance of a calculated basis set was shown to be equivalent to that of a measured basis set [23, 54]. Therefore, the detection errors observed in our study is not likely due to inaccurate spectral bases, but a consequence of the limited performance of 1H–MRS. For improved 2HG detection at short TE, we proposed incorporating measured baselines instead of using the built–in, modeled baselines currently employed in LCModel. One of the disadvantages with the proposed approach would be the difficulty of lipid quantification, which may also be important for glioma research, given that lipid is associated with glioblastomas and its status after treatment [47, 48]. At high field more detailed baseline information is known to be required due to higher spectral dispersion [20, 23]. However, it should be noted that with currently available hardware setting at 3.0T a better shimming and a comparable or even higher SNR than those obtained in our study can be attained. Specifically, whereas the mean linewidth of water was ~15 Hz for the mean voxel volume of ~9.6 mm3 in our study, a linewidth of as narrow as ~6 Hz was reported to be achievable at 3.0T for a voxel volume of 8 cm3  or even larger . In addition, while our data were acquired by using a single channel receiver coil, 8–32 channel receiver coils are used in clinical scanners [9, 10, 12]. As both SNR and spectral dispersion are coupled to influence the quantitative precision , the incorporation of voxel–specifically measured baselines is expected to improve 2HG detection at clinical field strength as well, and in this context our results at 9.4T can be informative for upcoming clinical studies. Finally, voxel–specific acquisition of metabolite–nulled spectra requires additional scan time. Thus, the total scan time required for a short TE spectrum and a baseline can be comparable to that required for J–difference editing [9, 10]. For the latter, 2HG can be detected in the J–difference (subtracted) spectrum, and quantification of other metabolites can also be performed from the reference spectrum (without editing pulses), but with the quantitative outcome potentially prone to error for all metabolites due to relaxation. The long TE single shot method  can directly detect 2HG with only half the scan time required for both J–difference editing and the short TE acquisition with baseline measurement. Therefore, the extra scan time can be dedicated for an additional spectrum at short TE. For such a long TE single shot method with an extra short TE spectrum, only 2HG is potentially subject to quantitative error due to relaxation. Upon validation in human studies of the proposed approach with short TE acquisition in combination with baseline measurement, the different pros and cons of these three different approaches for 2HG detection should be taken together in the study design.
In vivo detection of 2HG by using the conventional short TE approach is challenging even at 9.4T. While the proposed method should be validated in a larger number of animals and more importantly in human patients, the incorporation of voxel–specifically measured spectral baselines into the spectral basis set may potentially improve its performance.
S1 File. The 2HG quantification by LC-MS.
S2 File. The 2HG quantification by MRS.
S3 File. The linear regression between 2HGLC-MS and 2HGMRS.
Conceived and designed the experiments: HH SK HHL HRC SHC HK. Performed the experiments: HH SK HHL HRC WJX SHL CKP SP SHC HK. Analyzed the data: HH SK HHL HRC WJX SHL CKP SP SHC HK. Contributed reagents/materials/analysis tools: SHL CKP SP SHC HK. Wrote the paper: HH SK HHL HRC WJX SHL CKP SP SHC HK.
- 1. Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310(17):1842–50. doi: 10.1001/jama.2013.280319 pmid:24193082.
- 2. Olar A, Aldape KD. Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol. 2014;232(2):165–77. doi: 10.1002/path.4282 pmid:24114756; PubMed Central PMCID: PMC4138801.
- 3. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807–12. doi: 10.1126/science.1164382 pmid:18772396; PubMed Central PMCID: PMC2820389.
- 4. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. New Engl J Med. 2009;360(8):765–73. doi: 10.1056/NEJMoa0808710 pmid:19228619; PubMed Central PMCID: PMC2820383.
- 5. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science. 2009;324(5924):261–5. Epub 2009/04/11. doi: 10.1126/science.1170944 pmid:19359588; PubMed Central PMCID: PMC3251015.
- 6. Cairns RA, Mak TW. Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discov. 2013;3(7):730–41. doi: 10.1158/2159-8290.CD-13-0083 pmid:23796461.
- 7. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739–44. doi: 10.1038/nature08617 pmid:19935646; PubMed Central PMCID: PMC2818760.
- 8. Andronesi OC, Rapalino O, Gerstner E, Chi A, Batchelor TT, Cahill DP, et al. Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. J Clin Invest. 2013;123(9):3659–63. doi: 10.1172/JCI67229 pmid:23999439; PubMed Central PMCID: PMC3754248.
- 9. Andronesi OC, Kim GS, Gerstner E, Batchelor T, Tzika AA, Fantin VR, et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med. 2012;4(116):116ra4. doi: 10.1126/scitranslmed.3002693 pmid:22238332; PubMed Central PMCID: PMC3720836.
- 10. Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, Kovacs Z, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med. 2012;18(4):624–9. doi: 10.1038/nm.2682 pmid:22281806; PubMed Central PMCID: PMC3615719.
- 11. Chronaiou I, Stensjoen AL, Sjobakk TE, Esmaeili M, Bathen TF. Impacts of MR spectroscopic imaging on glioma patient management. Acta Oncol. 2014;53(5):580–9. doi: 10.3109/0284186X.2014.891046 pmid:24628262.
- 12. Pope WB, Prins RM, Albert Thomas M, Nagarajan R, Yen KE, Bittinger MA, et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol. 2012;107(1):197–205. doi: 10.1007/s11060-011-0737-8 pmid:22015945; PubMed Central PMCID: PMC3650613.
- 13. Allen PS, Thompson RB, Wilman AH. Metabolite-specific NMR spectroscopy in vivo. NMR Biomed. 1997;10(8):435–44. pmid:9542740.
- 14. Choi C, Ganji S, Hulsey K, Madan A, Kovacs Z, Dimitrov I, et al. A comparative study of short- and long-TE (1)H MRS at 3 T for in vivo detection of 2-hydroxyglutarate in brain tumors. NMR Biomed. 2013;26(10):1242–50. Epub 2013/04/18. doi: 10.1002/nbm.2943 pmid:23592268; PubMed Central PMCID: PMC3733061.
- 15. Tonjes M, Barbus S, Park YJ, Wang W, Schlotter M, Lindroth AM, et al. BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. Nat Med. 2013;19(7):901–8. doi: 10.1038/nm.3217 pmid:23793099.
- 16. Shi J, Sun B, Shi W, Zuo H, Cui D, Ni L, et al. Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation. Tumour Biol. 2015;36(2):655–62. doi: 10.1007/s13277-014-2644-z pmid:25283382.
- 17. Marin-Valencia I, Yang C, Mashimo T, Cho S, Baek H, Yang XL, et al. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab. 2012;15(6):827–37. Epub 2012/06/12. doi: 10.1016/j.cmet.2012.05.001 pmid:22682223; PubMed Central PMCID: PMC3372870.
- 18. Hofmann L, Slotboom J, Jung B, Maloca P, Boesch C, Kreis R. Quantitative 1H-magnetic resonance spectroscopy of human brain: Influence of composition and parameterization of the basis set in linear combination model-fitting. Magn Reson Med. 2002;48(3):440–53. Epub 2002/09/05. doi: 10.1002/mrm.10246 pmid:12210908.
- 19. McLean MA, Simister R. J., Barker G. J., Duncan J. S. Metabolite nulling improves reliability of LCModel analysis of short echo time spectroscopy. Proc Intl Soc Mag Reson Med. 2002;10:529.
- 20. Pfeuffer J, Tkac I, Provencher SW, Gruetter R. Toward an in vivo neurochemical profile: quantification of 18 metabolites in short-echo-time (1)H NMR spectra of the rat brain. J Magn Reson. 1999;141(1):104–20. doi: 10.1006/jmre.1999.1895 pmid:10527748.
- 21. Behar KL, Rothman DL, Spencer DD, Petroff OA. Analysis of macromolecule resonances in 1H NMR spectra of human brain. Magn Reson Med. 1994;32(3):294–302. Epub 1994/09/01. pmid:7984061.
- 22. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993;30(6):672–9. Epub 1993/12/01. pmid:8139448.
- 23. Cudalbu C, Mlynarik V, Gruetter R. Handling macromolecule signals in the quantification of the neurochemical profile. J Alzheimers Dis. 2012;31 Suppl 3:S101–15. doi: 10.3233/JAD-2012-120100 pmid:22543852.
- 24. Naressi A, Couturier C, Devos JM, Janssen M, Mangeat C, de Beer R, et al. Java-based graphical user interface for the MRUI quantitation package. MAGMA. 2001;12(2–3):141–52. pmid:11390270.
- 25. van den Boogaart A, Ala-Korpela M, Jokisaari J, Griffiths JR. Time and frequency domain analysis of NMR data compared: an application to 1D 1H spectra of lipoproteins. Magn Reson Med. 1994;31(4):347–58. Epub 1994/04/01. pmid:8208109.
- 26. Pels P, Ozturk-Isik E, Swanson MG, Vanhamme L, Kurhanewicz J, Nelson SJ, et al. Quantification of prostate MRSI data by model-based time domain fitting and frequency domain analysis. NMR Biomed. 2006;19(2):188–97. Epub 2006/01/18. doi: 10.1002/nbm.1008 pmid:16411280.
- 27. Kanowski M, Kaufmann J, Braun J, Bernarding J, Tempelmann C. Quantitation of simulated short echo time 1H human brain spectra by LCModel and AMARES. Magn Reson Med. 2004;51(5):904–12. doi: 10.1002/mrm.20063 pmid:15122672.
- 28. Barth RF. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J Neurooncol. 1998;36(1):91–102. pmid:9525831.
- 29. Wen H, Cho HR, Yun T, Kim H, Park CK, Lee SH, et al. Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism. J Neurochem. 2015;132(2):183–93. doi: 10.1111/jnc.12950 pmid:25251602.
- 30. Mlynarik V, Gambarota G, Frenkel H, Gruetter R. Localized short-echo-time proton MR spectroscopy with full signal-intensity acquisition. Magn Reson Med. 2006;56(5):965–70. doi: 10.1002/mrm.21043 pmid:16991116.
- 31. Slotboom J, Mehlkopf AF, Bovee WMMJ. The Effects of Frequency-Selective Rf Pulses on J-Coupled Spin-1/2 Systems. J Magn Reson Ser A. 1994;108(1):38–50. doi: 10.1006/jmra.1994.1086.
- 32. Tkac I, Starcuk Z, Choi IY, Gruetter R. In vivo 1H NMR spectroscopy of rat brain at 1 ms echo time. Magn Reson Med. 1999;41(4):649–56. Epub 1999/05/20. pmid:10332839.
- 33. Tkac I, Gruetter R. Methodology of H NMR Spectroscopy of the Human Brain at Very High Magnetic Fields. Appl Magn Reson. 2005;29(1):139–57. doi: 10.1007/BF03166960 pmid:20179773; PubMed Central PMCID: PMC2825674.
- 34. Dixon WT, Sardashti M, Castillo M, Stomp GP. Multiple inversion recovery reduces static tissue signal in angiograms. Magn Reson Med. 1991;18(2):257–68. doi: 10.1002/mrm.1910180202 pmid:2046511.
- 35. Penner J, Bartha R. Semi-LASER H MR spectroscopy at 7 Tesla in human brain: Metabolite quantification incorporating subject-specific macromolecule removal. Magn Reson Med. 2014. Epub 2014/08/02. doi: 10.1002/mrm.25380 pmid:25081993.
- 36. de Graaf RA, Brown PB, McIntyre S, Nixon TW, Behar KL, Rothman DL. High magnetic field water and metabolite proton T1 and T2 relaxation in rat brain in vivo. Magn Reson Med. 2006;56(2):386–94. Epub 2006/06/13. doi: 10.1002/mrm.20946 pmid:16767752.
- 37. Schaller B, Xin L, Gruetter R. Is the macromolecule signal tissue-specific in healthy human brain? A (1)H MRS study at 7 Tesla in the occipital lobe. Magn Reson Med. 2014;72(4):934–40. doi: 10.1002/mrm.24995 pmid:24407736.
- 38. Cabanes E, Confort-Gouny S, Le Fur Y, Simond G, Cozzone PJ. Optimization of residual water signal removal by HLSVD on simulated short echo time proton MR spectra of the human brain. J Magn Reson. 2001;150(2):116–25. doi: 10.1006/jmre.2001.2318 pmid:11384169.
- 39. Wylezinska M, Cobbold JF, Fitzpatrick J, McPhail MJ, Crossey MM, Thomas HC, et al. A comparison of single-voxel clinical in vivo hepatic 31P MR spectra acquired at 1.5 and 3.0 Tesla in health and diseased states. NMR Biomed. 2011;24(3):231–7. doi: 10.1002/nbm.1578 pmid:20949641.
- 40. Stanley JA, Pettegrew JW. Postprocessing method to segregate and quantify the broad components underlying the phosphodiester spectral region of in vivo (31)P brain spectra. Magn Reson Med. 2001;45(3):390–6. pmid:11241695.
- 41. Gottschalk M, Lamalle L, Segebarth C. Short-TE localised 1H MRS of the human brain at 3 T: quantification of the metabolite signals using two approaches to account for macromolecular signal contributions. NMR Biomed. 2008;21(5):507–17. Epub 2007/10/24. doi: 10.1002/nbm.1219 pmid:17955570.
- 42. Smith SA, Levante TO, Meier BH, Ernst RR. Computer-Simulations in Magnetic-Resonance—an Object-Oriented Programming Approach. J Magn Reson Ser A. 1994;106(1):75–105. doi: 10.1006/jmra.1994.1008.
- 43. Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed. 2000;13(3):129–53. pmid:10861994.
- 44. Ratiney H, Coenradie Y, Cavassila S, van Ormondt D, Graveron-Demilly D. Time-domain quantitation of 1H short echo-time signals: background accommodation. MAGMA. 2004;16(6):284–96. doi: 10.1007/s10334-004-0037-9 pmid:15168136.
- 45. Provencher SW. LCModel & LCMgui user's manual. 2014.
- 46. Tkac I, Rao R, Georgieff MK, Gruetter R. Developmental and regional changes in the neurochemical profile of the rat brain determined by in vivo 1H NMR spectroscopy. Magn Reson Med. 2003;50(1):24–32. doi: 10.1002/mrm.10497 pmid:12815675.
- 47. Seeger U, Klose U, Mader I, Grodd W, Nagele T. Parameterized evaluation of macromolecules and lipids in proton MR spectroscopy of brain diseases. Magn Reson Med. 2003;49(1):19–28. doi: 10.1002/mrm.10332 pmid:12509816.
- 48. Auer DP, Gossl C, Schirmer T, Czisch M. Improved analysis of 1H-MR spectra in the presence of mobile lipids. Magn Reson Med. 2001;46(3):615–8. Epub 2001/09/11. pmid:11550257.
- 49. Kim H, Wild JM, Allen PS. Strategy for the spectral filtering of myo-inositol and other strongly coupled spins. Magn Reson Med. 2004;51(2):263–72. Epub 2004/02/03. doi: 10.1002/mrm.10697 pmid:14755650.
- 50. Kim H, Thompson RB, Hanstock CC, Allen PS. Variability of metabolite yield using STEAM or PRESS sequences in vivo at 3.0 T, illustrated with myo-inositol. Magn Reson Med. 2005;53(4):760–9. Epub 2005/03/31. doi: 10.1002/mrm.20434 pmid:15799042.
- 51. Chaumeil MM, Larson PE, Woods SM, Cai L, Eriksson P, Robinson AE, et al. Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma. Cancer Res. 2014;74(16):4247–57. doi: 10.1158/0008-5472.CAN-14-0680 pmid:24876103; PubMed Central PMCID: PMC4134724.
- 52. Opstad KS, Bell BA, Griffiths JR, Howe FA. Toward accurate quantification of metabolites, lipids, and macromolecules in HRMAS spectra of human brain tumor biopsies using LCModel. Magn Reson Med. 2008;60(5):1237–42. doi: 10.1002/mrm.21496 pmid:18836999.
- 53. Lee Y, Jee HJ, Noh H, Kang GH, Park J, Cho J, et al. In vivo (1)H-MRS hepatic lipid profiling in nonalcoholic fatty liver disease: an animal study at 9.4 T. Magn Reson Med. 2013;70(3):620–9. Epub 2012/10/02. doi: 10.1002/mrm.24510 pmid:23023916.
- 54. Cudalbu C, Cavassila S, Rabeson H, van Ormondt D, Graveron-Demilly D. Influence of measured and simulated basis sets on metabolite concentration estimates. NMR Biomed. 2008;21(6):627–36. doi: 10.1002/nbm.1234 pmid:18085510.